


PHARMACEUTICAL 2023



Sigilon Therapeutics Inc. Rank 264 of 446





PHARMACEUTICAL 2023



Sigilon Therapeutics Inc. Rank 264 of 446

The relative strengths and weaknesses of Sigilon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sigilon Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Sigilon Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 35%, being 8.4% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	74,411
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,994
Liabilities, Non-Current	17,142
Other Assets	10,013
Other Compr. Net Income	-419
Other Expenses	0
Other Liabilities	0
Other Net Income	105
Other Revenues	12,944
Property and Equipment	2,854
Research and Development	37,631
Selling, General and Administrative Expense	18,979

Output Variable	Value in 1000 USD
Assets	87,278
Liabilities	48,136
Expenses	56,610
Revenues	12,944
Stockholders Equity	39,142
Net Income	-43,561
Comprehensive Net Income	-43,770
Economic Capital Ratio	35%

